Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Leuprorelin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths) |
| B | ACTIVE_COMPARATOR | LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy. |
| C | EXPERIMENTAL | LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) |
| D | EXPERIMENTAL | LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy. |
| Name | Type | Description |
|---|---|---|
| Leuprorelin Acetate | DRUG | LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI). |
| Zoledronic Acid | DRUG | Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy. |
| Conventional external beam therapy | RADIATION | The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons. |
Inclusion Criteria: * Histological confirmation of adenocarcinoma of the prostate in the three months prior to randomisation * Gleason primary and secondary pattern reported. If the volume of tumour in biopsies is too small for the pathologist to allocate a secondary pattern, the primary pattern al...
Top 20 of 53 competitors
Leuprorelin is used for the treatment of Prostate Cancer. It is an investigational small molecule being studied in the Phase 3 RADAR trial, which evaluates androgen deprivation combined with radiotherapy in patients with prostate cancer.
Leuprorelin targets the androgen receptor pathway, as it is used in androgen deprivation therapy for prostate cancer. The RADAR trial specifically combines leuprorelin with radiotherapy to assess its efficacy in this patient population.
Leuprorelin is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker ABT. The drug is currently in Phase 3 clinical development for prostate cancer.
Leuprorelin is in Phase 3 clinical development. It is an investigational drug, not yet approved, and is being studied in the completed RADAR trial for prostate cancer.
Leuprorelin is associated with one clinical trial, NCT00193856, titled 'RADAR Trial - Randomised Androgen Deprivation and Radiotherapy'. This Phase 3 trial enrolled 1,071 male participants aged 18 years and older in Australia and New Zealand, and it has been completed.
Leuprorelin is also known by other names, though specific alternative names are not provided in the available information. It is a small molecule used in androgen deprivation therapy for prostate cancer.